On March 28, 2025, OncoZenge announced that the Company had entered an agreement granting Molteni Farmaceutici exclusive rights and for a commercial partnership to introduce BupiZenge™ in Europe (EU27, EEA, Switzerland, and United Kingdom).

The agreement includes, among other, milestone payments of EUR 250,000 upon execution of the agreement and EUR 250,000 at the successful completion of the planned clinical phase III study.

The initial milestone payment, amounting to approximately SEK 2.8m was received with value date april 11, 2025, and will be included in income and the financial position of OncoZenge as of March 31, 2025.

BupiZenge™ - Potential to be the leading treatment for oral pain.
 

For additional information, please contact:
Michael Owens, CFO, mobile: +46 73 324 4988, e-mail: michael.owens@oncozenge.se

Certified Adviser
OncoZenge's Certified Adviser is Redeye AB.

OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden

About this release
The information in this release was submitted for publication, through the agency of the contact persons set out above, at 09:45 CEST on April 11, 2025.

About OncoZenge
OncoZenge is dedicated to developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options fall short, often due to insufficient pain relief or significant side effects. BupiZenge™ is a novel oral lozenge formulation of bupivacaine, a local anesthetic with decades of clinical experience. The lead indication for BupiZenge™ is oral pain caused by oral mucositis, an inflammatory condition affecting millions of cancer patients. Oral mucositis leads to severe physical and psychological distress, representing a significant unmet medical need for an effective, opioid-sparing treatment. In Phase 2 trials, BupiZenge™ demonstrated substantially better pain relief compared to the standard of care.

OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.